Apoptosis Evasion: the Role of Survival Pathways in Prostate Cancer Progression and Therapeutic Resistance

Overview

Journal J Cell Biochem

Specialties Biochemistry
Cell Biology

Date 2005 Oct 11

PMID 16216007

Citations 54

Authors

Shaun McKenzie

Natasha Kyprianou

Affiliations

Soon will be listed here.

Abstract

The ability of a tumor cell population to grow exponentially represents an imbalance between cellular proliferation and cellular attrition. There is an overwhelming body of evidence suggesting the ability of tumor cells to avoid programmed cellular attrition, or apoptosis, is a major molecular force driving the progression of human tumors. Apoptotic evasion represents one of the true hallmarks of cancer and appears to be a vital component in the immunogenic, chemotherapeutic, and radiotherapeutic resistance that characterizes the most aggressive of human cancers [Hanahan and Weinberg, 2000]. The challenges in the development of effective treatment modalities for advanced prostate cancer represent a classic paradigm of the functional significance of anti-apoptotic pathways in the development of therapeutic resistance.

Citing Articles

8-Br-cGMP activates HSPB6 and increases the antineoplastic activity of quinidine in prostate cancer.

Feng Y, Huang Z, Lu F, Song L, Liu R, Zhang Y Cell Death Discov. 2024; 10(1):90.

PMID: 38374143 PMC: 10876707. DOI: 10.1038/s41420-024-01853-3.

Flavones: The Apoptosis in Prostate Cancer of Three Flavones Selected as Therapeutic Candidate Models.

Jeong S, Kim H, Park M, Bhosale P, Abusaliya A, Won C Int J Mol Sci. 2023; 24(11).

PMID: 37298192 PMC: 10252627. DOI: 10.3390/ijms24119240.

Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.

Nepali P, Kyprianou N Front Endocrinol (Lausanne). 2023; 14:1160267.

PMID: 37091854 PMC: 10113530. DOI: 10.3389/fendo.2023.1160267.

Androgen receptor signaling-mitochondrial DNA-oxidative phosphorylation: A critical triangle in early prostate cancer.

Sakellakis M, Flores L Curr Urol. 2023; 16(4):207-212.

PMID: 36714229 PMC: 9875216. DOI: 10.1097/CU9.0000000000000120.

The E3 Ligase TRIM25 Impairs Apoptotic Cell Death in Colon Carcinoma Cells via Destabilization of Caspase-7 mRNA: A Possible Role of hnRNPH1.

Nasrullah U, Stanke K, Recknagel V, Bozkurt S, Wurzel P, Gauer S Cells. 2023; 12(1).

PMID: 36611995 PMC: 9818768. DOI: 10.3390/cells12010201.

References

Ghafar M, Anastasiadis A, Chen M, Burchardt M, Olsson L, Xie H . Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells. Prostate. 2002; 54(1):58-67. DOI: 10.1002/pros.10162. View

McCarty M . Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther. 2004; 3(4):349-80. DOI: 10.1177/1534735404270757. View

Mimeault M, Pommery N, Henichart J . New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors. 2003; 21(1):1-14. DOI: 10.1080/0897719031000094921. View

Matthews E, Yang T, Janulis L, Goodwin S, Kundu S, Karpus W . Down-regulation of TGF-beta1 production restores immunogenicity in prostate cancer cells. Br J Cancer. 2000; 83(4):519-25. PMC: 2374659. DOI: 10.1054/bjoc.2000.1257. View

Suh J, Rabson A . NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J Cell Biochem. 2003; 91(1):100-17. DOI: 10.1002/jcb.10729. View

Vicentini C, Festuccia C, Gravina G, Angelucci A, Marronaro A, Bologna M . Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol. 2003; 129(3):165-74. DOI: 10.1007/s00432-003-0420-3. View

Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y . Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2004; 23(10):1838-44. DOI: 10.1038/sj.onc.1207304. View

Arnold J, Isaacs J . Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer. 2002; 9(1):61-73. PMC: 4124629. DOI: 10.1677/erc.0.0090061. View

Dhanalakshmi S, Singh R, Agarwal C, Agarwal R . Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene. 2002; 21(11):1759-67. DOI: 10.1038/sj.onc.1205240. View

10.

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

11.

Chen F . Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control. Cancer Res. 2004; 64(22):8135-8. DOI: 10.1158/0008-5472.CAN-04-2096. View

12.

Muenchen H, Lin D, Walsh M, Keller E, Pienta K . Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res. 2000; 6(5):1969-77. View

13.

Teicher B . Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 2002; 20(1-2):133-43. DOI: 10.1023/a:1013177011767. View

14.

Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C . Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer. 2003; 10(2):279-89. DOI: 10.1677/erc.0.0100279. View

15.

Bruckheimer E, Kyprianou N . Bcl-2 antagonizes the combined apoptotic effect of transforming growth factor-beta and dihydrotestosterone in prostate cancer cells. Prostate. 2002; 53(2):133-42. DOI: 10.1002/pros.10143. View

16.

Konig J, Senge T, Allhoff E, Konig W . Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004; 58(2):121-9. DOI: 10.1002/pros.10317. View

17.

Yuan X, Whang Y . PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene. 2002; 21(2):319-27. DOI: 10.1038/sj.onc.1205054. View

18.

Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G . EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer. 2004; 112(1):78-86. DOI: 10.1002/ijc.20362. View

19.

Amantana A, London C, Iversen P, Devi G . X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004; 3(6):699-707. View

20.

Balkwill F, Coussens L . Cancer: an inflammatory link. Nature. 2004; 431(7007):405-6. DOI: 10.1038/431405a. View